Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 […]
Fennec Pharmaceuticals plans to present detailed results from their Phase 2 STS-J01 clinical study of Pedmark® in Japan at the International Society of Pediatric Oncology (SIOP) meeting in 2026. This open-label, single-arm trial aimed to assess the effectiveness of Pedmark® in preventing cisplatin-induced ototoxicity in pediatric patients with various solid tumors.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
